共 50 条
- [41] An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY StudyBLOOD, 2015, 126 (23)Durrant, Simon T.Nagler, ArnonVannucchi, Alessandro M.Lavie, DavidChuah, CharlesPassamonti, FrancescoGisslinger, Heinzle Coutre, PhilippGopalakrishna, PrashanthMahuzier, BruyereMo, ShuyuanMartinez-Lopez, Joaquin
- [42] Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsINVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 670 - 681Rodon, JordiBrana, IreneSiu, Lillian L.De Jonge, Maja J.Homji, NatashaMills, DavidDi Tomaso, EmmanuelleSarr, CelineTrandafir, LuciaMassacesi, CristianEskens, FerryBendell, Johanna C.
- [43] HARMONY: An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis (MF)BLOOD, 2014, 124 (21)Durrant, SimonKoren-Michowitz, MayaLavie, DavidMartinez-Lopez, JoaquinVannucchi, Alessandro M.Passamonti, FrancescoStalbovskaya, ViktoriyaAtienza, EdricIommazzo, DanaGopalakrishna, PrashanthGisslinger, Heinz
- [44] Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue SarcomasPLOS ONE, 2015, 10 (09):Anderson, Jennifer L.Park, AnnAkiyama, RyanTap, William D.Denny, Christopher T.Federman, Noah
- [45] Discovery of BKM120, a pan class I PI3 kinase inhibitor in phase I/II clinical trialsABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240Burger, Matthew T.Pecchi, SabinaWagman, AllanNi, Zhi-JieKnapp, MarkAtallah, GordanaPfister, KeithNg, SimonSmith, AaronPick, TeresaFrazier, KellyVerhagen, JoelleZhang, YanchenBartulis, SarahHendricksen, TomIwanowicz, EdwinHazenadar, JoshuaHuh, KayAshash, AhmadXin, XiaohuaMenezes, DanielMerritt, HanneWiesmann, MarionVoliva, Charles
- [46] Phase II study of the PI3K inhibitor BKM120 monotherapy in patients with advanced or recurrent endometrial carcinoma: ENDOPIK, GINECO Study.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Heudel, Pierre-EtienneFabbro, MichelRoemer-Becuwe, CeliaTreilleux, IsabelleKaminsky, Marie-ChristineArnaud, AntoineJoly, FlorenceForestier, Sophie RocheHerve, RobertRay-Coquard, Isabelle
- [47] BKM120 combined with vemurafenib in vemurafenib-refractory BRAF mutant metastatic melanoma: Two cases.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Algazi, Alain PatrickPosch, ChristianOrtiz-Urda, SusanaCockerill, AlysonMunster, Pamela N.Daud, Adil
- [48] A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)Patnaik, AkashKung, JustinLoda, MassimoTaplin, Mary-EllenLis, RosinaKantoff, Philip W.Balk, Steven P.Bubley, Glenn J.
- [49] A phase Ib study of BKM120 combined with abiraterone acetate for castrate-resistant, metastatic prostate cancer.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Patnaik, AkashLoda, MassimoKung, JustinWu, JimTaplin, Mary-EllenKantoff, Philip W.Cantley, LewisBalk, Steven P.Bubley, Glenn J.
- [50] Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM)JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Wen, Patrick Y.Yung, W. K. AlfredMellinghoff, Ingo K.Lamborn, KathleenRamkissoon, ShaktiCloughesy, Timothy FrancisRinne, MikaelOmuro, Antonio Marcilio PadulaDeAngelis, Lisa MarieGilbert, Mark R.Chi, Andrew S.Batchelor, TracyColman, HowardChang, Susan MarinaMassacesi, CristianDiTomaso, EmmanuellePrados, MichaelReardon, David A.Ligon, Keith L.